Recipharm AB:企業の戦略的SWOT分析

◆英語タイトル:Recipharm AB - Strategic SWOT Analysis Review
◆商品コード:GDPH133157SA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:45
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Recipharm AB – Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – GlobalData’s summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.

Highlights

Recipharm AB (Recipharm) is a contract development and manufacturing organization (CDMO) that offers manufacturing, and development and technology services. The company’s manufacturing services include contract manufacturing of pharmaceuticals such as semi-solids, and oral liquids, solid dose, sterile products, besides clinical trial materials including APIs and other drugs. Recipharm’s development and technology services supports customers from initial product concept to the approved commercial pharmaceutical drug. It includes services such as raw material supply, formulation, validated analytical methods, among others. The company operates in the UK, Germany, Spain, Italy, Sweden, France, Portugal, India, Israel and the US. Recipharm is headquartered in Stockholm, Sweden.

Recipharm AB Key Recent Developments

Mar 02,2021: Recipharm names 2020 International Environmental Award winner
Feb 10,2021: Recipharm bolsters biologics offering
Jan 28,2021: Recipharm publishes report for the fourth quarter and full year 2020
Dec 09,2020: Recipharm invests USD 2.5 million in clinical GMP capacity for active pharmaceutical ingredients
Nov 10,2020: Recipharm invests in its pMDI valves production capacity

Reasons to Buy

- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Recipharm AB – Key Facts
Recipharm AB – Key Employees
Recipharm AB – Key Employee Biographies
Recipharm AB – Major Products and Services
Recipharm AB – History
Recipharm AB – Company Statement
Recipharm AB – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Recipharm AB – Business Description
Business Segment: ADS
Overview
Performance
Business Segment: D&L
Overview
Performance
Business Segment: MFG-S
Overview
Performance
Business Segment: MFG-SO
Overview
Performance
Geographical Segment: France
Performance
Geographical Segment: Germany
Performance
Geographical Segment: India
Performance
Geographical Segment: Italy
Performance
Geographical Segment: Other
Performance
Geographical Segment: Portugal
Performance
Geographical Segment: Spain
Performance
Geographical Segment: Sweden
Performance
Geographical Segment: UK
Performance
Recipharm AB – Corporate Strategy
Recipharm AB – SWOT Analysis
SWOT Analysis – Overview
Recipharm AB – Strengths
Recipharm AB – Weaknesses
Recipharm AB – Opportunities
Recipharm AB – Threats
Recipharm AB – Key Competitors
Section 3 – Company’s Lifesciences Financial Deals and Alliances
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Recipharm AB, Recent Deals Summary
Section 4 – Company’s Recent Developments
Mar 02, 2021: Recipharm names 2020 International Environmental Award winner
Feb 10, 2021: Recipharm bolsters biologics offering
Jan 28, 2021: Recipharm publishes report for the fourth quarter and full year 2020
Dec 09, 2020: Recipharm invests USD 2.5 million in clinical GMP capacity for active pharmaceutical ingredients
Nov 10, 2020: Recipharm invests in its pMDI valves production capacity
Nov 05, 2020: Recipharm publishes its interim report for the third quarter 2020
Oct 13, 2020: Recipharm invests EUR 2.6 million in Kaysersberg facility
Jul 27, 2020: Recipharm publishes its interim report for the second quarter 2020
Jul 13, 2020: Recipharm doubles EBIT and expects second quarter results to be stronger than analyst consensus
May 07, 2020: Recipharm publishes its interim report January-March 2020
Section 5 – Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

List of Tables
Recipharm AB, Key Facts
Recipharm AB, Key Employees
Recipharm AB, Key Employee Biographies
Recipharm AB, Major Products and Services
Recipharm AB, History
Recipharm AB, Other Locations
Recipharm AB, Subsidiaries
Recipharm AB, Key Competitors
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Recipharm AB, Recent Deals Summary

★海外企業調査レポート[Recipharm AB:企業の戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • UCB Inc-製薬・医療分野:企業M&A・提携分析
    Summary UCB Inc (UCB), a subsidiary of UCB SA is a healthcare solutions provider that offers therapeutics. The company develops products with an emphasis on central nervous system and immunology therapeutic domains. Its products include cimzia, vimpat, keppra XR, neupro, tussionex pennkinetic, metad …
  • Great Wolf Resorts Inc:戦略・SWOT・企業財務分析
    Great Wolf Resorts Inc - Strategy, SWOT and Corporate Finance Report Summary Great Wolf Resorts Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Idemitsu Kosan Co Ltd (5019):石油・ガス:M&Aディール及び事業提携情報
    Summary Idemitsu Kosan Co Ltd (Idemitsu) is an integrated energy company that explores, produces, refines, and sells oil and gas, lubricants, and petroleum products. The company manufactures agricultural chemicals, agricultural materials, and other chemicals. It explores, develops and extracts coal, …
  • Prothena Corp Plc (PRTA):企業の財務・戦略的SWOT分析
    Summary Prothena Corp Plc (Prothena) discovers and develops therapies for the treatment of neurological disorders. It is evaluating Prasinezumab (PRX002/RG7935), a monoclonal antibody targeting alpha-synuclein protein, against Parkinson’s disease and other related synucleinopathies; and PRX004, an i …
  • Nisshinbo Holdings Inc. (3105):企業の財務・戦略的SWOT分析
    Nisshinbo Holdings Inc. (3105) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Vaxart Inc (VXRT):企業の財務・戦略的SWOT分析
    Vaxart Inc (VXRT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Immunomic Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Immunomic Therapeutics Inc (ITI) is a clinical-stage biotechnology company that develops patented lysosomal-associated membrane protein or lamp technology based nucleic acid immunotherapy platforms. The company’s vaccines utilize the body’s natural biochemistry to develop immune response inc …
  • Goodwin Biotechnology Inc-製薬・医療分野:企業M&A・提携分析
    Summary Goodwin Biotechnology Inc (GBI), a subsidiary of Wallace Pharmaceuticals Pvt Ltd is a healthcare company that develops and manufactures vaccines, monoclonal antibodies, recombinant proteins and bioconjugates. The company offers cell culture, purification, bioconjugation, biosimilars, aseptic …
  • Austrian Post:企業の戦略・SWOT・財務情報
    Austrian Post - Strategy, SWOT and Corporate Finance Report Summary Austrian Post - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Leap Therapeutics Inc (LPTX):医療機器:M&Aディール及び事業提携情報
    Summary Leap Therapeutics Inc (Leap Therapeutics), formerly HealthCare Pharmaceuticals Inc, is a clinical-stage biopharmaceutical company that develops novel therapeutics to treat patients with cancer. The company’s pipeline products include DKN-01, a humanized monoclonal antibody that targets the D …
  • British Columbia Ferry Services Inc.:企業の戦略的SWOT分析
    British Columbia Ferry Services Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • Comvita Ltd (CVT):企業の財務・戦略的SWOT分析
    Comvita Ltd (CVT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • University of Alabama at Birmingham-製薬・医療分野:企業M&A・提携分析
    Summary University of Alabama at Birmingham (UAB), a subsidiary of University of Alabama System is an educational university that offers undergraduate and graduate programs. The university provides graduate programs in arts and sciences, health professions, medicine, nursing, business, dentistry, ed …
  • Sagent Pharmaceuticals, Inc.:企業のM&A・事業提携・投資動向
    Sagent Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Sagent Pharmaceuticals, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …
  • EVN AG (EVN):企業の財務・戦略的SWOT分析
    EVN AG (EVN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pote …
  • Punjab National Bank (PNB):電力:M&Aディール及び事業提携情報
    Summary Punjab National Bank (PNB) offers retail and commercial banking, agricultural and international banking, and other financial services. Its retail and commercial banking portfolio offers credit and debit cards, corporate and retail loans, deposit services, cash management, and export and impo …
  • Microsoft Corporation (MSFT):企業の財務・戦略的SWOT分析
    Microsoft Corporation (MSFT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Chimerix Inc (CMRX):企業の財務・戦略的SWOT分析
    Summary Chimerix Inc (Chimerix) is a bio pharmaceutical company that develops, discovers, and commercializes novel and oral antiviral therapeutics. The company’s brincidofovir, an oral nucleotide analog to treat dsDNA viruses, adenovirus, cytomegalovirus, BK virus and herpes simplex viruses. Chimeri …
  • Sypris Solutions, Inc.:企業の戦略・SWOT・財務情報
    Sypris Solutions, Inc. - Strategy, SWOT and Corporate Finance Report Summary Sypris Solutions, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • PT Tigaraksa Satria Tbk (TGKA):企業の財務・戦略的SWOT分析
    PT Tigaraksa Satria Tbk (TGKA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆